How to Predict the Absorption Rate of New Chemical Entities
02/23/2012
David Elder | GlaxoSmithKline | improving solubility | solubility | poorly soluble drug | absorption | drug absorption
Current estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins Andrea Charles from Pharma IQ, to discuss the ever-increasing numbers of poorly soluble drugs coming to market and utilising in silico and computational modelling to better predict absorption of new chemical entities.
David Elder | GlaxoSmithKline | improving solubility | solubility | poorly soluble drug | absorption | drug absorption
This interview was filmed at Pharma IQ's 7th Improving Solubility conference in June 2011.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
-
Disruptive Technologies Slowly Affecting Global Clinical Trial Supply -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing -
Roche Video News: New Hope for Arthritis Patients with Treatment Four Times More Likely to Halt Progression -
The Secrets of Preparing Impressive and Memorable Presentations – Mike Ashton of ABCG Video -
Merck KGaA: Building a Strategic Partnership with your CMO -
Valea Video Series - Introduction to Valea -
Valea Video Series - An Overview -
Valea Video Series - Life Sciences & Chemistry -
Valea Video Series - Mechanics -
Valea Video Series - Legal Services
You Should Check Out:
* = required.
Not a member yet? Sign up
|
|
Useful info
|
|
|
Useful info
|
Events of Interest
-
Enhancing the Bioavailability of Low-Solubility Compounds
February 18, 2010
Register Now -
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now -
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now




Replies (0)
Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!